胃癌药物市场：依治疗方法、应用、通路和地区划分

预计到 2026 年，胃癌治疗市场规模将达到 56 亿美元，到 2033 年将达到 91 亿美元，2026 年至 2033 年的年复合成长率（CAGR）为 7.2%。

根据世界癌症研究基金会（WCRF）2018年的报告，胃癌是全球第五大常见癌症，不分性别。胃癌的病因多种多样，包括不健康的饮食、吸烟、肥胖、饮酒以及幽门螺旋桿菌病菌感染。英国癌症研究中心2016年的资料显示，英国每年新增的胃癌病例中，有三分之一与幽门螺旋桿菌感染有关。胃癌筛检可以确定病菌感染的分期，并据此指导治疗。标靶药物治疗常用于治疗胃癌，因为它能够针对快速分裂的细胞，且副作用较少。目前，针对HER2标靶药物正在研发中，用于治疗进行性胃癌。例如，Pertuzumab、曲妥珠单抗和化疗的联合治疗目前正在进行治疗转移性胃食道交界处癌或胃癌的III期临床试验。

市场动态

全球胃癌发生率的不断上升预计将推动胃癌治疗市场的扩张。例如，根据世界癌症研究基金会（WCRF）2018年的数据，当年约有100万例胃癌确诊病例。此外，人口老化是患胃癌的高风险因素，男性尤其容易罹患此病。例如，根据美国癌症协会（ACS）2014年的报告，胃癌患者的平均确诊年龄为68岁。报告也指出，每年确诊的胃癌患者中，十分之六为65岁及以上的老年人，使得胃癌成为男性第四大常见癌症。

然而，胃癌药物市场面临的一大挑战是治疗费用高昂，这在许多国家对中低收入家庭来说难以负担。根据2017年发表在权威期刊《Oncotarget》的数据，胃癌药物（包括曲妥珠单抗）的费用四周可达8,000美元，一年可达9,6,000美元。

本次调查的主要特点

• 本报告以 2017 年为基准年，对胃癌药物市场、市场规模以及预测期（2018-2026 年）的复合年增长率（%）进行了详细分析。
• 该报告重点介绍了各个细分市场的潜在商机，并为该市场说明了一个具有吸引力的投资提案矩阵。
• 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 该研究根据以下参数对全球胃癌治疗市场的主要企业进行了分析：公司概况、财务表现、产品系列、地理分布、分销策略、关键发展和策略。
• 主要企业包括辉瑞公司、礼来公司、葛兰素史克公司、库尼尔製药株式会社、第一三共株式会社、默克集团、阿斯特捷利康公司、大冢控股株式会社、赛诺菲公司、罗氏公司、小野药品工业株式会社、百时美恆瑞宝公司、江苏苏苏公司。此外，还有吉利德科学公司、新基公司、大鹏药品工业株式会社、波士顿生物医学公司和默克公司。
• 本报告的研究结果将使负责人和经营团队能够就即将推出的产品、政府政策、技术创新、市场扩张和行销策略做出明智的决策。
• 这份全球胃癌药物市场报告的目标受众是业内各相关人员，包括投资者、产品製造商、经销商、供应商、研究和咨询公司、新参与企业和金融分析师。

目录

第一章 研究目标与前提条件

• 调查目的
• 先决条件
• 简称

第二章 市场概览

• 报告概述
  • 市场定义和范围
• 执行摘要

第三章 市场动态、监理及趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 法规环境
• 产品上市及核准情况
• PEST分析
• 波特分析
• 市场机会
• 法规环境
• 重大进展
• 产业趋势

4. 2020-2033年全球胃癌药物市场（依治疗方法）

• 激酶抑制剂
• 核苷代谢抑制剂
• 细胞週期蛋白
• VEGF抗体
• HER2受体拮抗剂
• CAR-T细胞疗法曲妥珠单抗
• 曲妥珠单抗

5. 2020-2033年全球胃癌药物市场（依应用领域划分）

• 腺癌
• 胃肠道基质肿瘤
• 类癌肿瘤

6. 2020-2033年全球胃癌药物市场依通路划分

• 医院药房
• 零售药房
• 网路药房

7. 2020-2033年全球胃癌药物市场（按地区划分）

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲国家
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 亚太其他地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第八章 竞争情势

• Pfizer Inc.
• Eli Lilly and Company
• GlaxoSmithKline Plc.
• Kuhnil Pharmaceutical Co. Ltd.
• Daiichi Sankyo Co. Ltd.
• Merck KGaA
• AstraZeneca Plc.
• Otsuka Holdings Co. Ltd.
• Sanofi SA
• F. Hoffmann-La Roche Ltd.
• Ono Pharmaceutical Co. Ltd.
• Bristol-Myers Squibb（BMS）
• Jiangsu HengRui Medicine Co. Ltd.
• Gilead Science Inc.
• Celgene Corporation
• Taiho Pharmaceutical
• Boston Biomedical Inc.
• Merck &Co.

第九章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第十章 参考文献与调查方法

• 参考
• 调查方法
• 关于本公司

Stomach Cancer Drugs Market is estimated to be valued at USD 5,600 Mn in 2026 and is expected to reach USD 9,100 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.

Stomach cancer is the fifth most common cancer globally regardless of gender as reported by the World Cancer Research Fund (WCRF) in 2018. There are many factors which cause stomach cancer such as unhealthy diet, smoking, obesity, alcohol, and Helicobacter pylori infection. According to the Cancer Research U.K. data of 2016, one out of three stomach cancer cases is related to Helicobacter pylori infection in the U.K. annually. Stomach cancer tests identify the stage of the cancer and the patient is treated accordingly. Targeted drug therapies are frequently used to treat stomach cancer as these drugs target the rapidly dividing cells and have less side effects. Drugs that target HER2 are under developmental studies to treat advanced stomach cancer. For instance, pertuzumab in combination with trastuzumab and chemotherapy is under phase 3 clinical trials to treat metastatic gastroesophageal junction or gastric cancer.

Market Dynamics

Increasing prevalence of stomach cancer worldwide is expected to boost the stomach cancer drugs market size. For instance, according to WCRF data of 2018, around one million cases of stomach cancer were diagnosed in 2018. Furthermore, increasing geriatric population is at a high risk of developing stomach cancer and men are more vulnerable to developing stomach cancer. For instance, according to the American Cancer Society (ACS) report in 2014, the average age of people diagnosed with stomach cancer is 68. As per the same source, six out of ten people diagnosed with stomach cancer annually are 65 or older, and stomach cancer is the fourth most common cancer in men.

However, the major challenge in the stomach cancer drugs market are the high expenses related to treatment of stomach cancer, which are not affordable to the middle to low income families in most countries. According to a data published in Oncotarget (impact journal) in 2017, the cost of stomach cancer drugs (considering Trastuzumab) can reach up to US$ 8,000 for four weeks and annually it can reach up to US$ 96,000.

Key features of the study

• This report provides in-depth analysis of the stomach cancer drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global stomach cancer drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, government initiatives, technological up-gradation, market expansion, and marketing tactics
• The global stomach cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for stomach cancer drugs market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• Therapy Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Kinase Inhibitors
  • Nucleoside Metabolic Inhibitors
  • Anthracyclines
  • VEGF Antibodies
  • HER2 Receptor Antagonists
  • Car T Cell Therapy Trastuzumab
  • Trastuzumab
• Application Insights (Revenue, USD Mn, 2026 - 2033)
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
• Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
  • Endoscopic Surgery
  • Surgical Suite
  • Dental Surgery
  • Others
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa
• Key Players Insights
  • Pfizer Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc.
  • Kuhnil Pharmaceutical Co. Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Merck KGaA
  • AstraZeneca Plc.
  • Otsuka Holdings Co. Ltd.
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • Ono Pharmaceutical Co. Ltd.
  • Bristol-Myers Squibb (BMS)
  • Jiangsu HengRui Medicine Co. Ltd.
  • Gilead Science Inc.
  • Celgene Corporation
  • Taiho Pharmaceutical
  • Boston Biomedical Inc.
  • Merck & Co.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Stomach Cancer Drugs Market, By Therapy Type
  • Global Stomach Cancer Drugs Market, By Application
  • Global Stomach Cancer Drugs Market, By Distribution Channel
  • Global Stomach Cancer Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trend

4. Global Stomach Cancer Drugs Market, By Therapy Type, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Kinase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Nucleoside Metabolic Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Anthracyclines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• VEGF Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• HER2 Receptor Antagonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Car T Cell Therapy Trastuzumab
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Trastuzumab
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Stomach Cancer Drugs Market, By Application, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Adenocarcinomas
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Gastrointestinal Stromal Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Carcinoid Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Stomach Cancer Drugs Market, By Distribution Channel, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

7. Global Stomach Cancer Drugs Market, By Region, 2020 - 2033, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline Plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Kuhnil Pharmaceutical Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Daiichi Sankyo Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca Plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Holdings Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ono Pharmaceutical Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb (BMS)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Jiangsu HengRui Medicine Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Science Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Celgene Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Taiho Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boston Biomedical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us